NDAOPHTHALMICGEL
Approved
Oct 2008
Lifecycle
LOE Approaching
Competitive Pressure
25/100
Data completeness
4/8 — Partial
Drug data last refreshed 20h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
AKTEN is a topical ophthalmic gel formulation of lidocaine hydrochloride anhydrous approved for ocular anesthesia. It works by stabilizing neuronal membranes and inhibiting ionic fluxes required for nerve impulse initiation and conduction. The product is indicated for local anesthetic use in ophthalmology procedures.
$0.001BPart D
LOE Approaching3mo to LOEProduct is in late-stage lifecycle with minimal market penetration (14 Part D claims in 2023), signaling a small, potentially shrinking brand team.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Why This Matters for Your Career
Patent cliff in less than a year — expect lifecycle management and generic defense hiring
Worked on AKTEN at Thea Pharma? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.